FAQ

capmatinib

Known as: 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide 
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
02420152017

Related topics

Related topics

4 relations

Narrower (1)

INC280

Broader (2)

ImidazolesTriazines
Receptor Tyrosine Kinase Inhibition

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
capmatinib
Imidazoles
Triazines
INC280
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Aberrant c-Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c-Met… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
2017
2017
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells
Sorafenib displays a limited efficacy for advanced hepatocellular carcinoma (HCC). Some patients with HCC initially respond to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells
Although many epidermal growth factor receptor (EGFR)-mutated lung cancer patients initially benefit from the EGFR-inhibitor… (More)
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
2017
2017
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Background Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the… (More)
Is this relevant?
Review
2017
Review
2017
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for the treatment of non-small cell lung… (More)
Is this relevant?
Review
2017
Review
2017
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Non-small cell lung cancer (NSCLC) inevitably develops resistance to epidermal growth factor receptor (EGFR) tyrosine kinase… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2016
2016
The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice.
The receptor tyrosine kinase mesenchymal-epithelial transition factor (c-Met) sits at the interface between controlled cellular… (More)
Is this relevant?
2016
2016
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
PURPOSE To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
Using avatars to win the fight over BRAF inhibitor resistance.
Patient-derived xenografts (PDXs) that are generated by transplanting fresh human tumor tissue into immunodeficient mice (avatars… (More)
  • figure 1
Is this relevant?
2015
2015
IN THE SPOTLIGHT MET Receptor Juxtamembrane Exon 14 Alternative Spliced Variant: Novel Cancer Genomic Predictive Biomarker
802 | CANCER DISCOVERY AUGUST 2015 www.aacrjournals.org 1 Mary Babb Randolph Cancer Center, Robert C. Byrd Health Sciences Center… (More)
  • figure 1
Is this relevant?